The SCHOOL of nature: IV. Learning from viruses

Self/Nonself - Immune Recognition and Signaling

Volumn 1, Issue 4, 2010, Pages 282-298

  Sigalov, Alexander B ^a  

^a SignaBlok Inc   (United States)

Author keywords

Antiviral therapy; Cell activation; Cytoplasmic homointeractions; HIV; Host virus interactions; Human cytomegalovirus; Human immunodeficiency virus; Human T cell lymphotropic virus; Immune disorders; Immune response; Inhibitors; MIRR; Multichain immune recognition receptors; Natural cytotoxicity receptor; Natural killer cell; Novel immunomodulators; Pattern recognition receptors; SCHOOL model; Signal transduction; Signaling chain homooligomerization model; T cell receptor; Therapeutic targets; Toll like receptors; Transmembrane interactions; Viral entry; Viral modulation; Viral pathogenesis; Viral replication; Viruses

Indexed keywords

NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; T LYMPHOCYTE RECEPTOR;

ADENOVIRUS; AMINO ACID SEQUENCE; ARENAVIRUS; ARTICLE; ASTROVIRUS; BORNA DISEASE VIRUS; BUNYAVIRUS; CALICIVIRUS; CIRCOVIRIDAE; CORONAVIRUS; CYTOMEGALOVIRUS; FILOVIRIDAE; FLAVIVIRUS; HEPADNAVIRIDAE; HERPES VIRUS; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; MOLECULAR MECHANICS; NONHUMAN; ORTHOMYXOVIRUS; PAPOVAVIRUS; PARAMYXOVIRUS; PARVOVIRUS; PICORNAVIRUS; POXVIRUS; REOVIRUS; RETROVIRUS; RHABDOVIRUS; SARS CORONAVIRUS; SIGNAL TRANSDUCTION; SIGNALING CHAIN HOMOOLIGOMERIZATION PLATFORM; TOGAVIRUS; VIRUS CELL INTERACTION; VIRUS CLASSIFICATION; VIRUS ENTRY; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 79851486792     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.1.4.13279     Document Type: Article

References (231)

1. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449:819-26.
2. Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity 2007; 27:370-83.
3. Takeuchi O, Akira S. Recognition of viruses by innate immunity. Immunol Rev 2007; 220:214-24.
4. Schroder M, Bowie AG. An arms race: innate antiviral responses and counteracting viral strategies. Biochem Soc Trans 2007; 35:1512-4.
5. Loo YM, Gale M Jr. Viral regulation and evasion of the host response. Curr Top Microbiol Immunol 2007; 316:295-313.
6. Keller BC, Johnson CL, Erickson AK, Gale M Jr. Innate immune evasion by hepatitis C virus and West Nile virus. Cytokine Growth Factor Rev 2007; 18:535-44.
7. Coscoy L. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol 2007; 7:391-401.
8. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol 2006; 8:907-22.
9. van Wamel WJ, Rooijakkers SH, Ruyken M, van Kessel KP, van Strijp JA. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on beta-hemolysin-converting bacteriophages. J Bacteriol 2006; 188:1310-5.
10. Rajagopalan S, Long EO. Viral evasion of NK-cell activation. Trends Immunol 2005; 26:403-5.
11. Kosugi I, Kawasaki H, Arai Y, Tsutsui Y. Innate immune responses to cytomegalovirus infection in the developing mouse brain and their evasion by virus-infected neurons. Am J Pathol 2002; 161:919-28.
12. Haller O, Weber F. Pathogenic viruses: smart manipulators of the interferon system. Curr Top Microbiol Immunol 2007; 316:315-34.
13. Saito T, Gale M Jr. Principles of intracellular viral recognition. Curr Opin Immunol 2007; 19:17-23.
14. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
15. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005; 560:11-8.
16. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54:1-13.
17. Doly J, Civas A, Navarro S, Uze G. Type I interferons: expression and signalization. Cell Mol Life Sci 1998; 54:1109-21.
18. Kunzi MS, Pitha PM. Interferon targeted genes in host defense. Autoimmunity 2003; 36:457-61.
19. Le Page C, Genin P, Baines MG, Hiscott J. Interferon activation and innate immunity. Rev Immunogenet 2000; 2:374-86.
20. Ozato K, Tailor P, Kubota T. The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem 2007; 282:20065-9.
21. Galligan CL, Murooka TT, Rahbar R, Baig E, Majchrzak-Kita B, Fish EN. Interferons and viruses: signaling for supremacy. Immunol Res 2006; 35:27-40.
22. Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res 2005; 15:407-22.
23. Bonjardim CA. Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses-and viruses counteract IFN action. Microbes Infect 2005; 7:569-78.
24. Cebulla CM, Miller DM, Sedmak DD. Viral inhibition of interferon signal transduction. Intervirology 1999; 42:325-30.
25. Garcia-Sastre A. Mechanisms of inhibition of the host interferon alpha/beta-mediated antiviral responses by viruses. Microbes Infect 2002; 4:647-55.
26. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000; 81:2341-64.
27. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001; 12:143-56.
28. Yang I, Kremen TJ, Giovannone AJ, Paik E, Odesa SK, Prins RM, et al. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 2004; 100:310-9.
29. Agrawal S, Kishore MC. MHC class I gene expression and regulation. J Hematother Stem Cell Res 2000; 9:795-812.
30. Thomas HE, Parker JL, Schreiber RD, Kay TW. IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Invest 1998; 102:1249-57.
31. Gruschwitz MS, Vieth G. Upregulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum 1997; 40:540-50.
32. Dhib-Jalbut SS, Xia Q, Drew PD, Swoveland PT. Differential upregulation of HLA class I molecules on neuronal and glial cell lines by virus infection correlates with differential induction of IFN-beta. J Immunol 1995; 155:2096-108.
33. Chang CH, Hammer J, Loh JE, Fodor WL, Flavell RA. The activation of major histocompatibility complex class I genes by interferon regulatory factor-1 (IRF-1). Immunogenetics 1992; 35:378-84.
34. Beniers AJ, Peelen WP, Debruyne FM, Schalken JA. HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. Int J Cancer 1991; 48:709-16.
35. Giacomini P, Fisher PB, Duigou GJ, Gambari R, Natali PG. Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). Anticancer Res 1988; 8:1153-61.
36. Keegan AD, Paul WE. Multichain immune recognition receptors: similarities in structure and signaling pathways. Immunol Today 1992; 13:63-8.
37. Sigalov A. Multi-chain immune recognition receptors: spatial organization and signal transduction. Semin. Immunol 2005; 17:51-64.
38. Sigalov AB. Multichain immune recognition receptor signaling: different players, same game? Trends Immunol 2004; 25:583-9.
39. Sigalov AB, ed. Multichain Immune Recognition Receptor Signaling: From Spatiotemporal Organization to Human Disease. New York: Springer-Verlag 2008; 357.
40. Sigalov AB. Immune cell signaling: a novel mechanistic model reveals new therapeutic targets. Trends Pharmacol Sci 2006; 27:518-24.
41. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9:465-79.
42. Krogsgaard M, Davis MM. How T cells 'see' antigen. Nat Immunol 2005; 6:239-45.
43. DeFranco AL. B-cell activation 2000. Immunol Rev 2000; 176:5-9.
44. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004; 41:599-613.
45. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005; 25:1-18.
46. Takai T. Fc receptors: their diverse functions in immunity and immune disorders. Springer Semin Immunopathol 2006; 28:303-4.
47. Colonna M, Nakajima H, Navarro F, Lopez-Botet M. A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukoc Biol 1999; 66:375-81.
48. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002; 38:637-60.
49. Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res 2004; 114:221-33.
50. Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol 2006; 6:457-64.
51. Kanazawa N, Tashiro K, Miyachi Y. Signaling and immune regulatory role of the dendritic cell immunoreceptor (DCIR) family lectins: DCIR, DCAR, dectin-2 and BDCA-2. Immunobiology 2004; 209:179-90.
52. Biassoni R, Cantoni C, Falco M, Pende D, Millo R, Moretta L, et al. Human natural killer cell activating receptors. Mol Immunol 2000; 37:1015-24.
53. Biassoni R, Cantoni C, Marras D, Giron-Michel J, Falco M, Moretta L, et al. Human natural killer cell receptors: insights into their molecular function and structure. J Cell Mol Med 2003; 7:376-87.
54. Aoki N, Kimura S, Xing Z. Role of DAP12 in innate and adaptive immune responses. Curr Pharm Des 2003; 9:7-10.
55. Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA 1999; 96:9792-6.
56. van den Berg TK, Yoder JA, Litman GW. On the origins of adaptive immunity: innate immune receptors join the tale. Trends Immunol 2004; 25:11-6.
57. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006; 7:1266-73.
58. Takai T. Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology 2005; 115:433-40.
59. Nakahashi C, Tahara-Hanaoka S, Totsuka N, Okoshi Y, Takai T, Ohkohchi N, et al. Dual assemblies of an activating immune receptor, MAIR-II, with ITAM-bearing adapters DAP12 and FcRgamma chain on peritoneal macrophages. J Immunol 2007; 178:765-70.
60. Fujimoto M, Takatsu H, Ohno H. CMRF-35-like molecule-5 constitutes novel paired receptors, with CMRF-35-like molecule-1, to transduce activation signal upon association with FcRgamma. Int Immunol 2006; 18:1499-508.
61. Stewart CA, Vivier E, Colonna M. Strategies of natural killer cell recognition and signaling. Curr Top Microbiol Immunol 2006; 298:1-21.
62. Reth M. Antigen receptor tail clue. Nature 1989; 338:383-4.
63. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993; 72:767-78.
64. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med 2000; 192:1059-68.
65. Manolios N, Bonifacino JS, Klausner RD. Transmembrane helical interactions and the assembly of the T cell receptor complex. Science 1990; 249:274-7.
66. Call ME, Pyrdol J, Wiedmann M, Wucherpfennig KW. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 2002; 111:967-79.
67. Michnoff CH, Parikh VS, Lelsz DL, Tucker PW. Mutations within the NH2-terminal transmembrane domain of membrane immunoglobulin (Ig) M alters Ig alpha and Ig beta association and signal transduction. J Biol Chem 1994; 269:24237-44.
68. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15:203-34.
69. Feng J, Garrity D, Call ME, Moffett H, Wucherpfennig KW. Convergence on a distinctive assembly mechanism by unrelated families of activating immune receptors. Immunity 2005; 22:427-38.
70. Feng J, Call ME, Wucherpfennig KW. The assembly of diverse immune receptors is focused on a polar membrane-embedded interaction site. PLoS Biol 2006; 4:142.
71. Bakema JE, de Haij S, den Hartog-Jager CF, Bakker J, Vidarsson G, van Egmond M, et al. Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction. J Immunol 2006; 176:3603-10.
72. Varin-Blank N, Metzger H. Surface expression of mutated subunits of the high affinity mast cell receptor for IgE. J Biol Chem 1990; 265:15685-94.
73. Stevens TL, Blum JH, Foy SP, Matsuuchi L, DeFranco AL. A mutation of the mu transmembrane that disrupts endoplasmic reticulum retention. Effects on association with accessory proteins and signal transduction. J Immunol 1994; 152:4397-406.
74. Zidovetzki R, Rost B, Pecht I. Role of transmembrane domains in the functions of B- and T-cell receptors. Immunol Lett 1998; 64:97-107.
75. Blum JH, Stevens TL, DeFranco AL. Role of the mu immunoglobulin heavy chain transmembrane and cytoplasmic domains in B cell antigen receptor expression and signal transduction. J Biol Chem 1993; 268:27236-45.
76. Ra C, Jouvin MH, Kinet JP. Complete structure of the mouse mast cell receptor for IgE (Fc epsilon RI) and surface expression of chimeric receptors (rat-mouse-human) on transfected cells. J Biol Chem 1989; 264:15323-7.
77. Kim WM, Sigalov AB. Viral pathogenesis, modulation of immune receptor signaling and treatment. Adv Exp Med Biol 2008; 640:325-49.
78. Sigalov AB. Interaction between HIV gp41 fusion peptide and T cell receptor: putting the puzzle pieces back together. Faseb J 2007; 21:1633-4.
79. Sigalov AB. Transmembrane interactions as immunotherapeutic targets: lessons from viral pathogenesis. Adv Exp Med Biol 2007; 601:335-44.
80. Sigalov AB. SCHOOL model and new targeting strategies. Adv Exp Med Biol 2008; 640:268-311.
81. Sigalov AB. The SCHOOL of nature. I. Transmembrane signaling. Self/Nonself-Immune Recognition and Signaling 2010; 1:4-39.
82. Sigalov AB. The SCHOOL of nature. II. Protein order, disorder and oligomericity in transmembrane signaling. Self/Nonself-Immune Recognition and Signaling 2010; 1:89-102.
83. Sigalov AB. New therapeutic strategies targeting transmembrane signal transduction in the immune system. Cell Adh Migr 2010; 4:255-67.
84. Sigalov AB. The SCHOOL of nature. III. From mechanistic understanding to novel therapies. Self/Nonself-Immune Recognition and Signaling 2010; 3:192-224.
85. Sigalov AB. Novel mechanistic insights into viral modulation of immune receptor signaling. PLoS Pathog 2009; 5:1000404.
86. Lwoff A, Tournier P. The classification of viruses. Annu Rev Microbiol 1966; 20:45-74.
87. Lwoff A, Horne R, Tournier P. A system of viruses. Cold Spring Harb Symp Quant Biol 1962; 27:51-5.
88. Baltimore D. Expression of animal virus genomes. Bacteriol Rev 1971; 35:235-41.
89. Vlasak R, Luytjes W, Spaan W, Palese P. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci USA 1988; 85:4526-9.
90. Higa HH, Rogers GN, Paulson JC. Influenza virus hemagglutinins differentiate between receptor determinants bearing N-acetyl-, N-glycollyl- and N,O-diacetylneuraminic acids. Virology 1985; 144:279-82.
91. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988; 333:426-31.
92. Gentsch JR, Pacitti AF. Differential interaction of reovirus type 3 with sialylated receptor components on animal cells. Virology 1987; 161:245-8.
93. Paul RW, Choi AH, Lee PW. The alpha-anomeric form of sialic acid is the minimal receptor determinant recognized by reovirus. Virology 1989; 172:382-5.
94. Paul RW, Lee PW. Glycophorin is the reovirus receptor on human erythrocytes. Virology 1987; 159:94-101.
95. Greve JM, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56:839-47.
96. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence and expression of a new member of the immunoglobulin superfamily. Cell 1989; 56:855-65.
97. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989; 56:849-53.
98. Tomassini JE, Graham D, DeWitt CM, Lineberger DW, Rodkey JA, Colonno RJ. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1989; 86:4907-11.
99. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312:763-7.
100. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312:767-8.
101. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47:333-48.
102. + T cells by a complex of the 110K viral protein and the T4 molecule. Science 1986; 231:382-5.
103. Sattentau QJ, Weiss RA. The CD4 antigen: physiological ligand and HIV receptor. Cell 1988; 52:631-3.
104. Durell SR, Martin I, Ruysschaert JM, Shai Y, Blumenthal R. What studies of fusion peptides tell us about viral envelope glycoprotein-mediated membrane fusion (review). Mol Membr Biol 1997; 14:97-112.
105. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70:777-810.
106. Epand RM. Fusion peptides and the mechanism of viral fusion. Biochim Biophys Acta 2003; 1614:116-21.
107. Teissier E, Pecheur EI. Lipids as modulators of membrane fusion mediated by viral fusion proteins. Eur Biophys J 2007; 36:887-99.
108. Weissenhorn W, Hinz A, Gaudin Y. Virus membrane fusion. FEBS Lett 2007; 581:2150-5.
109. White JM. Viral and cellular membrane fusion proteins. Annu Rev Physiol 1990; 52:675-97.
110. White JM. Membrane fusion. Science 1992; 258:917-24.
111. Daniels PS, Jeffries S, Yates P, Schild GC, Rogers GN, Paulson JC, et al. The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J 1987; 6:1459-65.
112. Hoekstra D, Kok JW. Entry mechanisms of enveloped viruses. Implications for fusion of intracellular membranes. Biosci Rep 1989; 9:273-305.
113. Lamb RA. Paramyxovirus fusion: a hypothesis for changes. Virology 1993; 197:1-11.
114. Marsh M, Helenius A. Virus entry into animal cells. Adv Virus Res 1989; 36:107-51.
115. Underwood PA, Skehel JJ, Wiley DC. Receptor-binding characteristics of monoclonal antibody-selected antigenic variants of influenza virus. J Virol 1987; 61:206-8.
116. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56:365-94.
117. Tyler KLaF, Bernard N. Fundamental Virology. Third Edition ed. Philadelphia, PA: Lippincott-Raven Publishers 1996; 161-206.
118. Center RJ, Leapman RD, Lebowitz J, Arthur LO, Earl PL, Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol 2002; 76:7863-7.
119. Weiss CD, Levy JA, White JM. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol 1990; 64:5674-7.
120. Zhang CW, Chishti Y, Hussey RE, Reinherz EL. Expression, purification and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer. J Biol Chem 2001; 276:39577-85.
121. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-8.
122. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85:1135-48.
123. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6.
124. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3and CKR-2b as fusion cofactors. Cell 1996; 85:1149-58.
125. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-7.
126. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384:184-7.
127. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384:179-83.
128. Quintana FJ, Gerber D, Kent SC, Cohen IR, Shai Y. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest 2005; 115:2149-58.
129. Sigalov AB. Multichain immune recognition receptor signaling: different players, same game? Trends Immunol 2004; 25:583-9.
130. Quintana FJ, Gerber D, Bloch I, Cohen IR, Shai Y. A structurally altered D,L-amino acid TCRalpha transmembrane peptide interacts with the TCRalpha and inhibits T-cell activation in vitro and in an animal model. Biochemistry 2007; 46:2317-25.
131. Wang XM, Djordjevic JT, Kurosaka N, Schibeci S, Lee L, Williamson P, et al. T-cell antigen receptor peptides inhibit signal transduction within the membrane bilayer. Clin Immunol 2002; 105:199-207.
132. Wang XM, Djordjevic JT, Bender V, Manolios N. T cell antigen receptor (TCR) transmembrane peptides colocalize with TCR, not lipid rafts, in surface membranes. Cell Immunol 2002; 215:12-9.
133. Manolios N, Collier S, Taylor J, Pollard J, Harrison LC, Bender V. T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Nat Med 1997; 3:84-8.
134. Amon MA, Ali M, Bender V, Chan YN, Toth I, Manolios N. Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. Biochim Biophys Acta 2006; 1763:879-88.
135. Manolios N, Ali M, Bender V. T-cell antigen receptor (TCR) transmembrane peptides: A new paradigm for the treatment of autoimmune diseases. Cell Adh Migr 2010; 4:273-83.
136. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242:1168-71.
137. DeMeritt IB, Milford LE, Yurochko AD. Activation of the NFkappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. J Virol 2004; 78:4498-507.
138. Mocarski E Jr, Hahn G, White KL, et al. Myeloid cell recruitment and function in pathogenesis and latency. In: Reddehase M, Ed. Cytomegaloviruses: Pathogenesis, Molecular Biology and Infection Control. Norfolk, United Kingdom: Caister Scientific Press 2006; 465-82.
139. Mocarski E, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe D, Howley PM, Ed. Fields Virology Philadelphia, PA: Lippincott Williams & WIlkins 2007; 2:2702-72.
140. Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci USA 2003; 100:11439-44.
141. Paulus C, Krauss S, Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc Natl Acad Sci USA 2006; 103:3840-5.
142. Wiertz E, Hill A, Tortorella D, Ploegh H. Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol Lett 1997; 57:213-6.
143. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005; 6:515-23.
144. Jones KS, Fugo K, Petrow-Sadowski C, Huang Y, Bertolette DC, Lisinski I, et al. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J Virol 2006; 80:8291-302.
145. Manel N, Taylor N, Kinet S, Kim FJ, Swainson L, Lavanya M, et al. HTLV envelopes and their receptor GLUT1, the ubiquitous glucose transporter: a new vision on HTLV infection? Front Biosci 2004; 9:3218-41.
146. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003; 115:449-59.
147. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7:365-78.
148. Pinon JD, Kelly SM, Price NC, Flanagan JU, Brighty DW. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein. J Virol 2003; 77:3281-90.
149. Andersen PS, Geisler C, Buus S, Mariuzza RA, Karjalainen K. Role of the T cell receptor ligand affinity in T cell activation by bacterial superantigens. J Biol Chem 2001; 276:33452-7.
150. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299:1713-6.
151. Daenke S, Booth S. HTLV-1-induced cell fusion is limited at two distinct steps in the fusion pathway after receptor binding. J Cell Sci 2000; 113:37-44.
152. Jones PL, Korte T, Blumenthal R. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem 1998; 273:404-9.
153. Wilson KA, Bar S, Maerz AL, Alizon M, Poumbourios P. The conserved glycine-rich segment linking the N-terminal fusion peptide to the coiled coil of human T-cell leukemia virus type 1 transmembrane glycoprotein gp21 is a determinant of membrane fusion function. J Virol 2005; 79:4533-9.
154. Wilson KA, Maerz AL, Poumbourios P. Evidence that the transmembrane domain proximal region of the human T-cell leukemia virus type 1 fusion glycoprotein gp21 has distinct roles in the prefusion and fusion-activated states. J Biol Chem 2001; 276:49466-75.
155. Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 1985; 230:453-5.
156. Ruegg CL, Monell CR, Strand M. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1. J Virol 1989; 63:3257-60.
157. Yaddanapudi K, Palacios G, Towner JS, Chen I, Sariol CA, Nichol ST, et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. Faseb J 2006; 20:2519-30.
158. Sullivan BM, Coscoy L. Downregulation of the T-cell receptor complex and impairment of T-cell activation by human herpesvirus 6 u24 protein. J Virol 2008; 82:602-8.
159. Min CK, Bang SY, Cho BA, Choi YH, Yang JS, Lee SH, et al. Role of amphipathic helix of a herpesviral protein in membrane deformation and T cell receptor downregulation. PLoS Pathog 2008; 4:000209.
160. Park J, Lee BS, Choi JK, Means RE, Choe J, Jung JU. Herpesviral protein targets a cellular WD repeat endosomal protein to downregulate T lymphocyte receptor expression. Immunity 2002; 17:221-33.
161. Kikuta H, Lu H, Tomizawa K, Matsumoto S. Enhancement of human herpesvirus 6 replication in adult human lymphocytes by monoclonal antibody to CD3. J Infect Dis 1990; 161:1085-7.
162. Roffman E, Frenkel N. Replication of human herpesvirus-6 in thymocytes activated by anti-CD3 antibody. J Infect Dis 1991; 164:617-8.
163. + T cell depletion. J Clin Immunol 2001; 21:218-26.
164. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M. Association of integrase, matrix and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci USA 1993; 90:6125-9.
165. Farnet CM, Haseltine WA. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 1991; 65:1910-5.
166. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997; 71:5382-90.
167. Turlure F, Devroe E, Silver PA, Engelman A. Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci 2004; 9:3187-208.
168. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69:5087-94.
169. Freed EaM MA. HIVs and Their Replication. In: Knipe DaH PM, Ed. Fields Virology. Philadelphia, PA: Lippincott WIlliams & Wilkins 2007; 1:12107-85.
170. Gibellini D, Vitone F, Schiavone P, Re MC. HIV-1 tat protein and cell proliferation and survival: a brief review. New Microbiol 2005; 28:95-109.
171. Amarapal P, Tantivanich S, Balachandra K, Matsuo K, Pitisutithum P, Chongsa-nguan M. The role of the Tat gene in the pathogenesis of HIV infection. Southeast Asian J Trop Med Public Health 2005; 36:352-61.
172. Seelamgari A, Maddukuri A, Berro R, de la Fuente C, Kehn K, Deng L, et al. Role of viral regulatory and accessory proteins in HIV-1 replication. Front Biosci 2004; 9:2388-413.
173. Strebel K. Virus-host interactions: role of HIV proteins Vif, Tat and Rev. Aids 2003; 17:25-34.
174. + T lymphocytes by the Nef protein of HIV-1. J Leukoc Biol 2006; 79:616-27.
175. Schrager JA, Marsh JW. HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci USA 1999; 96:8167-72.
176. Simmons A, Aluvihare V, McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 2001; 14:763-77.
177. Baur AS, Sawai ET, Dazin P, Fantl WJ, Cheng-Mayer C, Peterlin BM. HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity 1994; 1:373-84.
178. Djordjevic JT, Schibeci SD, Stewart GJ, Williamson P. HIV type 1 Nef increases the association of T cell receptor (TCR)-signaling molecules with T cell rafts and promotes activation-induced raft fusion. AIDS Res Hum Retroviruses 2004; 20:547-55.
179. Ahmad N, Venkatesan S. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 1988; 241:1481-5.
180. Garcia JV, Miller AD. Downregulation of cell surface CD4 by nef. Res Virol 1992; 143:52-5.
181. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350:508-11.
182. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2:338-42.
183. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10:661-71.
184. Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998; 8:483-95.
185. Swigut T, Shohdy N, Skowronski J. Mechanism for downregulation of CD28 by Nef. EMBO J 2001; 20:1593-604.
186. Munch J, Janardhan A, Stolte N, Stahl-Hennig C, Ten Haaft P, Heeney JL, et al. T-cell receptor: CD3 downregulation is a selected in vivo function of simian immunodeficiency virus Nef but is not sufficient for effective viral replication in rhesus macaques. J Virol 2002; 76:12360-4.
187. Munch J, Rajan D, Schindler M, Specht A, Rucker E, Novembre FJ, et al. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol 2007; 81:13852-64.
188. Schaefer TM, Bell I, Fallert BA, Reinhart TA. The T-cell receptor zeta chain contains two homologous domains with which simian immunodeficiency virus Nef interacts and mediates down-modulation. J Virol 2000; 74:3273-83.
189. Swigut T, Greenberg M, Skowronski J. Cooperative interactions of simian immunodeficiency virus Nef, AP-2 and CD3-zeta mediate the selective induction of T-cell receptor-CD3 endocytosis. J Virol 2003; 77:8116-26.
190. Bell I, Ashman C, Maughan J, Hooker E, Cook F, Reinhart TA. Association of simian immunodeficiency virus Nef with the T-cell receptor (TCR) zeta chain leads to TCR down-modulation. J Gen Virol 1998; 79:2717-27.
191. Lock M, Greenberg ME, Iafrate AJ, Swigut T, Muench J, Kirchhoff F, et al. Two elements target SIV Nef to the AP-2 clathrin adaptor complex, but only one is required for the induction of CD4 endocytosis. EMBO J 1999; 18:2722-33.
192. Schindler M, Munch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006; 125:1055-67.
193. Ye H, Choi HJ, Poe J, Smithgall TE. Oligomerization is required for HIV-1 Nef-induced activation of the Src family protein-tyrosine kinase, Hck. Biochemistry 2004; 43:15775-84.
194. Hodge DR, Chen YM, Samuel KP. Oligomerization of the HIV type 2 Nef protein: mutational analysis of the heptad leucine repeat motif and cysteine residues. AIDS Res Hum Retroviruses 1995; 11:65-79.
195. Kienzle N, Freund J, Kalbitzer HR, Mueller-Lantzsch N. Oligomerization of the Nef protein from human immunodeficiency virus (HIV) type 1. Eur J Biochem 1993; 214:451-7.
196. Poe JA, Smithgall TE. HIV-1 Nef dimerization is required for Nef-mediated receptor downregulation and viral replication. J Mol Biol 2009; 394:329-42.
197. Arold S, Hoh F, Domergue S, Birck C, Delsuc MA, Jullien M, et al. Characterization and molecular basis of the oligomeric structure of HIV-1 nef protein. Protein Sci 2000; 9:1137-48.
198. Sigalov AB, Kim WM, Saline M, Stern LJ. The intrinsically disordered cytoplasmic domain of the T cell receptor zeta chain binds to the nef protein of simian immunodeficiency virus without a disorder-to-order transition. Biochemistry 2008; 47:12942-4.
199. Williams M, Roeth JF, Kasper MR, Filzen TM, Collins KL. Human immunodeficiency virus type 1 Nef domains required for disruption of major histocompatibility complex class I trafficking are also necessary for coprecipitation of Nef with HLA-A2. J Virol 2005; 79:632-6.
200. Liu LX, Heveker N, Fackler OT, Arold S, Le Gall S, Janvier K, et al. Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions. J Virol 2000; 74:5310-9.
201. Schamel WW, Arechaga I, Risueno RM, van Santen HM, Cabezas P, Risco C, et al. Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med 2005; 202:493-503.
202. Fenard D, Yonemoto W, de Noronha C, Cavrois M, Williams SA, Greene WC. Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J Immunol 2005; 175:6050-7.
203. Fultz PN. Replication of an acutely lethal simian immunodeficiency virus activates and induces proliferation of lymphocytes. J Virol 1991; 65:4902-9.
204. Dehghani H, Brown CR, Plishka R, Buckler-White A, Hirsch VM. The ITAM in Nef influences acute pathogenesis of AIDS-inducing simian immunodeficiency viruses SIVsm and SIVagm without altering kinetics or extent of viremia. J Virol 2002; 76:4379-89.
205. Petit C, Buseyne F, Boccaccio C, Abastado JP, Heard JM, Schwartz O. Nef is required for efficient HIV-1 replication in cocultures of dendritic cells and lymphocytes. Virology 2001; 286:225-36.
206. Piguet V, Trono D. The Nef protein of primate lentiviruses. Rev Med Virol 1999; 9:111-20.
207. Albrecht B, Collins ND, Burniston MT, Nisbet JW, Ratner L, Green PL, et al. Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol 2000; 74:9828-35.
208. Albrecht B, D'Souza CD, Ding W, Tridandapani S, Coggeshall KM, Lairmore MD. Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory protein p12(I). J Virol 2002; 76:3493-501.
209. Bindhu M, Nair A, Lairmore MD. Role of accessory proteins of HTLV-1 in viral replication, T cell activation and cellular gene expression. Front Biosci 2004; 9:2556-76.
210. Hollsberg P, Ausubel LJ, Hafler DA. Human T cell lymphotropic virus type I-induced T cell activation. Resistance to TGFbeta1-induced suppression. J Immunol 1994; 153:566-73.
211. Mann DL, Martin P, Hamlin-Green G, Nalewaik R, Blattner W. Virus production and spontaneous cell proliferation in HTLV-I-infected lymphocytes. Clin Immunol Immunopathol 1994; 72:312-20.
212. Albrecht B, Lairmore MD. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev 2002; 66:396-406.
213. Ding W, Albrecht B, Kelley RE, Muthusamy N, Kim SJ, Altschuld RA, et al. Human T-cell lymphotropic virus type 1 p12(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T cells. J Virol 2002; 76:10374-82.
214. Ding W, Kim SJ, Nair AM, Michael B, Boris-Lawrie K, Tripp A, et al. Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation. J Virol 2003; 77:11027-39.
215. Nicot C, Mulloy JC, Ferrari MG, Johnson JM, Fu K, Fukumoto R, et al. HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. Blood 2001; 98:823-9.
216. Johnson JM, Mulloy JC, Ciminale V, Fullen J, Nicot C, Franchini G. The MHC class I heavy chain is a common target of the small proteins encoded by the 3' end of HTLV type 1 and HTLV type 2. AIDS Res Hum Retroviruses 2000; 16:1777-81.
217. Collins ND, Newbound GC, Albrecht B, Beard JL, Ratner L, Lairmore MD. Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood 1998; 91:4701-7.
218. Guyot DJ, Newbound GC, Lairmore MD. Signaling via the CD2 receptor enhances HTLV-1 replication in T lymphocytes. Virology 1997; 234:123-9.
219. Von Bonin A, Ehrlich S, Fleischer B. The transmembrane region of CD2-associated signal-transducing proteins is crucial for the outcome of CD2-mediated T-cell activation. Immunology 1998; 93:376-82.
220. Wild MK, Verhagen AM, Meuer SC, Schraven B. The receptor function of CD2 in human CD2 transgenic mice is based on highly conserved associations with signal transduction molecules. Cell Immunol 1997; 180:168-75.
221. Kimata JT, Palker TJ, Ratner L. The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway. J Virol 1993; 67:3134-41.
222. Tsukahara T, Ratner L. Substitution of HIV Type 1 Nef with HTLV-1 p12. AIDS Res Hum Retroviruses 2004; 20:938-43.
223. Fukumoto R, Dundr M, Nicot C, Adams A, Valeri VW, Samelson LE, et al. Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1. J Virol 2007; 81:9088-99.
224. Sigalov AB. Signaling chain homooligomerization (SCHOOL) model. Adv Exp Med Biol 2008; 640:121-63.
225. Enk AH, Knop J. T cell receptor mimic peptides and their potential application in T-cell-mediated disease. Int Arch Allergy Immunol 2000; 123:275-81.
226. Huynh NT, Ffrench RA, Boadle RA, Manolios N. Transmembrane T-cell receptor peptides inhibit B- and natural killer-cell function. Immunology 2003; 108:458-64.
227. Collier S, Bolte A, Manolios N. Discrepancy in CD3-transmembrane peptide activity between in vitro and in vivo T-cell inhibition. Scand J Immunol 2006; 64:388-91.
228. Manolios N, Huynh NT, Collier S. Peptides in the treatment of inflammatory skin disease. Australas J Dermatol 2002; 43:226-7.
229. Ali M, Salam NK, Amon M, Bender V, Hibbs DE, Manolios N. T-cell antigen receptor-alpha chain transmembrane peptides: correlation between structure and function. Int J Pept Res Ther 2006; 12:261-7.
230. Kurosaka N, Ali M, Byth K, Manolios N. The mode of anti-arthritic peptide delivery impacts on the severity and outcome of adjuvant induced arthritis. APLAR J Rheumatol 2007; 10:198-203.
231. Gerber D, Quintana FJ, Bloch I, Cohen IR, Shai Y. D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo. Faseb J 2005; 19:1190-2.